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Abstract 
Introduction: The effectiveness of oral anticoagulation therapy with warfarin (a vitamin K 
antagonist) in the treatment of thromboembolic disease, including stroke prophylaxis in 
patients with atrial fibrillation is well recognised. However, warfarin has a narrow therapeutic 
window and an unpredictable anticoagulation response, which make it difficult to achieve and 
maintain optimal anticoagulation. Various dietary factors, including sudden changes in eating 
patterns, can significantly alter anticoagulation control, thereby potentially exposing patients to 
the risk of bleeding or thromboembolic complications. Dietary vitamin K intake is a particularly 
important factor, given the mechanism of action of warfarin.  
Areas covered: In this review, we cover the sources of vitamin K and their potential effect of 
dietary vitamin K on anticoagulation response to warfarin. We also discuss the results of 
studies on the effect of vitamin K supplementation on anticoagulation stability. 
Expert Opinion/Commentary: A stable dietary vitamin K, promoted by daily oral vitamin K 
supplementation, can improve anticoagulation stability in patients on warfarin therapy. There 
is experimental evidence in animals that dietary vitamin K affects anticoagulation response to 
the direct thrombin inhibitor, ximelagatran. Whether dietary vitamin K affects anticoagulation 
response to direct oral anticoagulants (DOACs) in man remains to be investigated. 
 
Word count: 196 
 
Keywords: lifestyle, nutrition, thromboembolic disease, vitamin K antagonists, 
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Introduction 
Thromboembolic disease, including stroke in patients with atrial fibrillation (AF), 
accounts for significant morbidity, mortality and economic burden in the developed world. AF 
is a common cardiac arrhythmia that affects over 33.5 million people globally (1) and is the 
strongest known risk factor (5-fold) for stroke (2) with the association between atrial fibrillation 
and stroke of cardioembolic origin being widely recognised. (3) The percentage of atrial 
fibrillation-attributed strokes increases with age, with a 16-fold increase between patients aged 
50-59 and 80-89 years (1.5% v 23.5% respectively). (4) The total annual cost for stroke 
treatment in the USA between 2011 and 2012 was estimated to be $33 billion (5). Venous 
thromboembolism, including deep vein thrombosis and pulmonary embolism affect 133 per 
100.000 of the population in the USA. Further, venous thromboembolism recurs in about 30 % 
of individuals within the next 10 years. (6) 
Coumarins, such as warfarin, phenprocoumon and acenocoumarol, have been the 
mainstay of oral anticoagulation therapy for the treatment of thromboembolic disease for more 
than 65 years. Randomised controlled studies have demonstrated that anticoagulation therapy 
with warfarin significantly reduces the overall risk of stroke, its severity and the associated risk 
of death in patients with AF. (7, 8) Consequently, treatment guidelines advocate the use of 
warfarin prophylaxis in patients with AF at moderate-to-high risk of stroke. (9)  
Vitamin K (as vitamin K hydroquinone) is an essential cofactor needed for the -
carboxylation of glutamic acid residues located at the amino-terminals of the vitamin K-
dependent clotting proteins II, VII, IX and X, leading to their activation. (10) Coumarins cause 
anticoagulation by interfering with the cyclic interconversion of vitamin K hydroquinone (hence 
also referred to as ‘vitamin K antagonists’) thus reducing the activation of vitamin K-dependent 
clotting proteins.  
Achieving effective and safe anticoagulation with warfarin, however, is a major 
challenge in routine medical care because many factors can influence the pharmacodynamic 
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effect of this drug. Whilst several factors including concurrent disease, drugs and patient 
compliance have been identified as affecting warfarin requirements in a predictable way, the 
observed intra-individual variability in anticoagulation response to warfarin cannot be fully 
explained at the present. There is evidence that dietary factors can make a significant 
contribution to unstable control of anticoagulation. In this article, we will discuss the potential 
impact of dietary factors on patients receiving long-term oral anticoagulation therapy with 
warfarin for the treatment and prevention of thromboembolic disease and the positive influence 
of daily vitamin K supplementation on anticoagulation control. We will also point to the potential 
impact of dietary vitamin K on the pharmacological activity of the more recently developed 
direct oral anticoagulants (DOACs).  
 
Dietary factors and anticoagulation control 
1. Dietary vitamin K intake 
Vitamin K is a fat-soluble vitamin that is largely derived from the diet, predominantly as 
phylloquinone (vitamin K1), present notably in green leafy vegetables and vegetable oils 
(Table 1). Given that the activation of the main clotting factors (II, VII, IX and X) is dependent 
on vitamin K availability, anticoagulation control during warfarin therapy is highly sensitive to 
fluctuating levels of vitamin K in the diet. (11-13) 
As there is no detailed assessment of usual population intake in relation to measurable 
health outcomes, daily Recommended Dietary Requirement (RDA) for vitamin K cannot be 
set. The current “dietary reference value” of 1 g/kg (65-80 µg of phylloquinone/day in an 
average sized individual) is based on coagulation factor function; substantially higher 
recommended daily doses have been suggested because of findings that the requirement for 
vitamin K is greater for the extra-hepatic vitamin K-dependent proteins, including those found 
in bone (e.g. osteocalcin). (14) In 2001, the adequate intake (AI) level for vitamin K based on 
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consumption levels in healthy individuals was established (Table 2). Neither pregnancy nor 
lactation necessitate additional vitamin K uptake in women. (15) A previous study of dietary 
intake of vitamin K in a national sample of British elderly people demonstrated that 59% had 
an intake below 1 g/kg/day. (16)  
Of all the fat-soluble vitamins, vitamin K has the highest individual daily variation in both 
dietary intake and corresponding plasma concentrations. This is because, dark green 
vegetables which are the main source of vitamin K, are not consistently consumed on a daily 
basis. For example, in a study of post-menopausal women in New England, USA, intake 
ranged from 3-2761µg of phylloquinone/day. (17)  
Sudden changes in dietary vitamin K intake resulting in poor anticoagulation control 
may put patients at increased risk of potential life-threatening bleeding and thromboembolic 
complications. Indeed, prosthetic valve thrombosis (18) and myocardial infarction (19) have 
been reported in patients who increased their vitamin K intake during anticoagulation therapy, 
and in the case report by Walker (19) this was linked to the patient embarking on a vegetable-
rich, weight-reduction diet. Conversely, diffuse bruising (presumably due to enhanced 
anticoagulation) in one case report was linked to the patient stopping his consumption of large 
amounts of porcine liver, thereby reducing his vitamin K intake (18). Thus, it has been 
suggested that patients maintain a consistent dietary vitamin K intake during anticoagulation 
therapy, generally no more than 250 to 500 µg/day (20).  
An earlier crossover study in anticoagulated patients demonstrated an inverse 
relationship between vitamin K intake and anticoagulation response, as measured by the 
International Normalised Ratio (INR). (12) Another study in patients on chronic therapy with 
warfarin and with stable control of anticoagulation demonstrated that for every 100 g increase 
in vitamin K intake over the previous 4 days, INR value fell by 0.2 units (21), further clarifying 
the extent of the inter-relationship between dietary vitamin K and the INR. Consistent with 
these observations, Lubetsky et al. found that, INR values decreased in 32% (16/50) of 
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anticoagulated patients following a vitamin K intake of ≥250 µg/day. The patients had 
significantly lower median INR values (1.9 and 3.0, respectively; p<0.001) and required a 
higher maintenance steady state warfarin dose (5.7 and 3.5 mg/day, respectively; p<0.001), 
compared to those receiving <250 µg/day of vitamin K. (11) 
In order to reduce intra-patient variability in anticoagulation response, patients should 
maintain an adequate and consistent intake of dietary vitamin K that at least meets the current 
dietary reference value of 65-80 µg/day. Self-monitoring of vitamin K intake aids, such as the 
‘K-Card’, which was designed as a checklist of common foods and beverages providing ≥5 µg 
vitamin K per serving (Table 3), may be helpful in this regard. (22)  
  
2. Dietary supplements 
2.1 Enteral feeds 
Enteral feeds may be an unsuspected source of additional dietary vitamin K in patients 
receiving warfarin. Although a decrease in the vitamin K content of enteral feedings has been 
observed over the years (23), some feeds may contain for example up to 20 µg vitamin K per 
8 fl oz (237ml) serving (Table 4). This may explain why certain enteral feeds have been 
reported to lower the anticoagulant effect of warfarin. (24-26) Thus, it is important to consider 
the significant impact of enteral nutrition on anticoagulation response in patients on warfarin 
therapy. 
Vitamin K also plays a key role in anticoagulation control in children. The main sources 
of phylloquinone in neonates, especially preterm infants, are the prophylactic dose of 
phylloquinone given at birth, along with the vitamin K intake derived from either parenteral 
and/or enteral feeding. Breast-fed infants, due to low quantity of vitamin K in human milk, are 
more sensitive to the anticoagulant effect of warfarin compared to formula-fed infants. Infant 
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formula preparations with high vitamin K content frequently administered to pre-term neonates, 
lead to higher warfarin dose requirements. (27, 28)  
2.2. Other supplements 
Vitamin K is a constituent of many multivitamin preparations. The anticoagulant effect 
of vitamin K antagonists is lessened even by multivitamin formulations containing small 
amounts of vitamin K. In relation to this, Kurnik et al. reported three cases of patients treated 
with warfarin who had presented with sub-therapeutic INR after taking multivitamin 
supplements containing vitamin K, which necessitated an increase in warfarin dose with one 
patient experiencing major thrombosis. (29) One of the patients, whose warfarin requirements 
had increased from 45 to 60 mg per week, discontinued the multivitamin preparation without 
notifying her physician and subsequently experienced haematoma accompanied by an INR of 
13.2. (29) Consequent to these observations, patients are best advised to avoid multivitamin 
preparations containing vitamin K.  
There is evidence that vitamin E interferes with vitamin K metabolism, as demonstrated 
by an increase in PIVKA-II (protein induced by vitamin K absence factor II) plasma 
concentrations. (30, 31) Both vitamin K and vitamin E are metabolised by CYP4F2 enzyme, 
which may explain the basis for their interaction. (32) However, in a randomised double-blind 
study, vitamin E at relatively high doses (800 or 1200 IU/day) was shown to have no effect on 
warfarin anticoagulation. (33) 
Vitamin C has been reported to interact with warfarin in vitro. (34, 35) The suggested 
mechanisms of this interaction include enzyme induction leading to enhanced warfarin 
metabolism, potentiation of vitamin K activity, influence in either the synthesis or the rate of 
catabolism of the vitamin K-dependent clotting factors, and capillary fragility. (36) A more 
recent study in rats in vivo demonstrated that the co-administration of vitamin C with warfarin 
leads to an increase in the activity of coagulation factors II, VII, IX and X and a decrease in PT 
and APTT. (37) Contrary to these findings however, it has been reported that vitamin C does 
 Page 8 of 29 
 
not alter the anticoagulant effect of warfarin in either dogs or guinea pigs.(36, 38) In patients 
on chronic warfarin therapy, we found no association between dietary vitamin C levels (2.2–
95.9 μM) and warfarin dose requirement. (39)  
The provitamin coenzyme Q10 (ubidecarenone) is a dietary supplement taken for a 
range of cardiovascular disorders (40) and has been linked to decreased anticoagulation when 
taken with warfarin (41). Coenzyme Q10 is structurally related to vitamin K and thus may have 
procoagulant effects in anticoagulated patients. (42) There are four case reports of falls in INR 
values following the co-administration of coenzyme Q10 with warfarin and subsequent 
restoration of initial INR values after discontinuation of coenzyme Q10. (43-45) A study in 
patients receiving long-term anticoagulation therapy however found that concomitant 
coenzyme Q10 intake (100 mg/day) had no significant effect on warfarin dose requirements. 
(46) As, at the present, there are conflicting reports about the effect of coenzyme Q10 on 
anticoagulation response to warfarin, patients should be advised to, either avoid the 
concomitant use of coenzyme Q10, or for healthcare providers to perform additional INR tests 
when patients start or stop taking coenzyme Q10. 
Fish oils contain eicosapentaenoic and docosahexaenoic acids, which may inhibit 
vitamin K-dependent coagulation factors. One case report described elevated INR values 
when the patient concerned had taken fish oil supplement with warfarin. (47) However, this 
contrasts with the findings of an earlier placebo-controlled, randomised, double-blinded study 
in 16 patients receiving chronic warfarin therapy, in whom fish oil supplementation (3–
6 grams/day) was shown to have no significant effect on anticoagulation control. (48) In the 
absence of further information, patients are advised to discuss the possible interaction 
between fish oil supplements and warfarin with their healthcare provider. 
Recently, Cambria-Kiely reported the case of a 70-year-old man with 
hypertriglyceridaemia who was stable on long-term warfarin (INR 2.3–2.5) before he started 
drinking soya milk. Shortly thereafter, his INR dropped below the therapeutic range (1.6); when 
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he stopped taking soya milk, his INR returned to the therapeutic range. (49) Interestingly, while 
soybeans and soybean oil contain high amounts of vitamin K (see Table 1), soya milk contains 
only trace amounts of the vitamin. (49) Further confirmation of the existence of an interaction 
between warfarin and soya milk and the possible mechanism for such interaction is needed. 
In the absence of further information, patients on warfarin therapy should avoid introducing 
soya milk into their diet. 
Supplements containing L-carnitine have been found to enhance the anticoagulant 
effect of the vitamin K antagonist, acenocoumarol. The mechanism for such interaction is 
unclear. Whether L-carnitine also interacts with warfarin or phenprocoumon is unknown at this 
stage. Therefore, patients on vitamin K antagonists are advised to discuss with their healthcare 
provider the possible risks before taking L-carnitine. (50, 51)  
 
2.3. Plant materials 
Interactions between herbs and other plant material and warfarin are commonly 
reported, sometimes with serious consequences of major bleeding. (52) Theoretically, any 
herb or plant material that may contain compounds related to coumarin or salicylate can 
augment the anticoagulant effect of vitamin K antagonists, through inhibition of either blood 
clotting or platelet aggregation. (53) 
Up until 2014, thirty eight different herbs had been reported in the literature with the 
potential to interact with warfarin. Evidence suggests that the likelihood of an interaction with 
warfarin is high (level I) for four of these herbs, probable (level II) for three, possible (level III) 
for ten and doubtful (level IV) for twenty one. (54) 
Garlic, ginkgo, St. John's wort, cranberry, grapefruit, cannabis, chamomile and red 
clover have been identified as having major interaction with warfarin. (54) Few reports have 
linked the use of garlic and gingko biloba with bleeding; however, there is no evidence that 
they directly affect coagulation. Ginger has been shown to inhibit platelet aggregation. (53), 
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which may potentiate the anticoagulant effect of warfarin. There have been case reports of an 
interaction between St John’s wort (Hypericum perforatum) and vitamin K antagonists 
(warfarin, phenprocoumon), where the use of St John’s wort resulted in the lowering of INR 
and unstable control of anticoagulation. (55) A single case of raised INR after concomitant use 
of Angelica sinensis (Dong quai) and warfarin has been reported. (56) Enhanced 
anticoagulation and bleeding events have been reported after patients on warfarin therapy took 
the traditional Chinese medicine, Salvia miltiorrhiza (danshen). (53, 57) 
There have been several reports of interaction between warfarin and cranberry juice 
(58-60). For instance, an elderly patient on warfarin who had a poor appetite following a chest 
infection consumed very little except cranberry juice and was admitted to hospital 6 weeks 
later with an INR of >50. He died of gastrointestinal and pericardial haemorrhage. (61) The 
advice of the UK Committee on Safety of Medicines is to limit the intake of cranberry juice in 
patients taking warfarin. (61) The mechanism of the interaction between warfarin and cranberry 
juice is at present unclear. However, it has been suggested that the flavonoids present in 
cranberry juice, which can inhibit CYP2C9 enzyme responsible for (S)- warfarin metabolism, 
can explain the interaction between cranberry juice and warfarin. (62) It is plausible that vitamin 
C, also a constituent of cranberry juice, contributes to alteration in anticoagulation response to 
warfarin, possibly by a number of mechanisms, including alterations in warfarin metabolism, 
competition with vitamin K in binding to vitamin K epoxide reductase which is the target enzyme 
for warfarin, and the rate of loss or catabolism of the vitamin K-dependent clotting factors. 
It may also be pertinent to avoid the consumption of grapefruit juice given reports of 
enhanced warfarin anticoagulation after consuming grapefruit juice. (63) Although an earlier 
controlled study failed to demonstrate an interaction between warfarin and grapefruit juice (64), 
other studies have reported that grapefruit juice enhances the anticoagulant effect of warfarin 
by inhibiting mainly CYP3A4 and CYP2C9 enzymes involved in warfarin metabolism.  (65, 66) 
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Green tea, which is often taken as a dietary supplement because of its reputed health 
benefits (including antioxidant and antibacterial properties), contains substantial amounts of 
vitamin K and therefore drinking large amounts may antagonise the anticoagulant effects of 
warfarin. (67) Indeed, one report describes a warfarin-treated patient who experienced a 
marked decrease in INR after daily consumption of large amounts of green tea, with a 
subsequent INR increase when the beverage was discontinued (without a change in warfarin 
dosage). (68) In the absence of further information, patients receiving anticoagulation therapy 
are advised to discuss the consumption of green tea and its possible impact on warfarin 
anticoagulation response with their healthcare provider.  
 
2.4. Alcohol consumption 
Alcohol intake is another important factor in patients receiving warfarin, as this may 
increase or decrease the anticoagulant effect. Acute alcohol intake (e.g. ingestion of a few 
alcoholic drinks at a single sitting) may increase anticoagulation, via decreased hepatic 
metabolism of warfarin (69) or displacement of the drug from albumin with subsequent increase 
in unbound drug (70). Conversely, chronic consumption of alcohol may decrease the 
anticoagulant effect by activating cytochrome P450, thereby increasing the metabolism of 
warfarin (69). However, in an earlier literature review, Wells et al. concluded that alcohol 
potentiated warfarin anticoagulation only if the patient had concomitant liver disease. (71) A 
Dutch study found that although habitual alcohol consumption or heavy drinking 
(≥6 drinks/day) did not affect anticoagulation control, a recent decrease in alcohol intake 
increased the risk of having an INR value 6.0 and thus increasing the risk of bleeding in the 
patient. (72) A case report of a patient on warfarin with a low-dose beer consumption was 
found to be the cause of elevated INR. The authors recommended close monitoring of INR 
when alcohol is taken in combination with warfarin and other concomitant medication. (73) In 
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the absence of consistent data, it is clear that patients should either avoid alcohol or at least 
avoid erratic consumption of alcohol while receiving warfarin with close INR monitoring. 
 
2.5. Vitamin K supplementation 
Clinical experience indicates that only 50% to 60% of INRs measured are within target 
range in patients with monthly monitoring of treatment. (74) Low vitamin K levels cause a 
patient’s warfarin dose requirement to vary with even minor changes in vitamin K intake.  
Several recent studies have shown that daily oral supplementation with vitamin K could 
improve stability of anticoagulation control in patients who are more susceptible to dietary 
changes, because of their poor and erratic dietary vitamin K intake, such as the elderly. (21, 
75-77) A small study in 2005 demonstrated that vitamin K supplementation improved 
anticoagulation control, possibly due to the more steady activation of vitamin K–dependent 
clotting factors. (78) At the same time, our group demonstrated that patients with variably low 
dietary intake of vitamin K were more likely to have unstable control of anticoagulation 
compared to their matched stable counterparts. (79) Kim and colleagues in 2010 confirmed 
that patients with low vitamin K intake are more sensitive to minor changes in vitamin K intake 
and thus more likely to have unstable anticoagulation control. (80) Another prospective study 
proposed that a vitamin K-guided management strategy is clinically feasible for the 
maintenance of oral anticoagulation intensity. (81) 
Schurgers and colleagues investigated the safe initiation of vitamin K supplementation 
on anticoagulation response in healthy subjects. They studied the dose-response relationship 
of vitamin K supplementation on anticoagulation control and concluded that the administration 
of 100 µg of vitamin K daily did not significantly influence INR value. (82) Despite a study 
showing that 25 µg significantly reduced the INR in patients with low vitamin K status (83), it 
was later recommended that supplementation with a 100 µg vitamin K daily dose is preferable 
to negate any influence of variability in dietary vitamin K intake. (84)  
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In 2007, three separate studies on the effect of vitamin K supplementation on 
anticoagulation stability reported similar findings. In a double-blinded placebo controlled study, 
seventy patients with unstable control of anticoagulation were randomised to receive either 
150μg oral vitamin K, or placebo daily for 6 months. The study confirmed that vitamin K 
supplementation results in significant improvement in anticoagulation stability attributed to a 
reduction in inter-day variability in dietary vitamin K intake. (76) A second open label crossover 
study of 9 patients with unstable anticoagulation control showed a reduction in INR variability 
after 500μg of oral vitamin K supplementation daily. (75) Rombouts and colleagues also 
demonstrated the positive effect on anticoagulation control of 100μg vitamin K 
supplementation once daily for 24 weeks in an unselected group of 200 patients on chronic 
therapy with phenprocoumon. (77) 
A recent meta-analysis reported no beneficial effect of low-dose vitamin K 
supplementation on the reduction of clinically relevant adverse events in patients taking VKAs. 
(85) However, the meta-analysis lacked sufficient data to show that daily vitamin K 
supplementation has an impact on the incidence of adverse events in anticoagulated patients. 
Based upon the overwhelming body of evidence that daily vitamin K supplementation improves 
anticoagulation stability the American College of Chest Physicians (ACCP) guidelines 
recommend the use of vitamin K in patients with chronically unstable anticoagulation. (86) 
 
2.6 Potential interaction between dietary vitamin K and direct oral anticoagulants 
In recent years, several direct oral anticoagulants (DOACs), which selectively inhibit a 
single clotting factor [factor Xa or factor IIa (thrombin)] have been developed with the aim of 
providing a more predictable pharmacokinetics and pharmacodynamics, thus obviating the 
need for patient monitoring. The factor IIa inhibitor, dabigatran, and factor Xa inhibitors, 
rivaroxaban, apixaban and edoxaban, have been provided license for the treatment of 
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thrombosis as well as prevention of stroke after having demonstrated non-inferiority to warfarin 
in their clinical effectiveness for stroke prophylaxis in patients with atrial fibrillation. (87-90) It 
is generally accepted that, unlike coumarins, DOACs do not interact with dietary vitamin K. 
This is because of the perception that the mode of action of these agents, which exert their 
pharmacological activity by inhibition of a specific clotting protein, is different to that of 
coumarins which inhibit the recycling of vitamin K, necessary for the gamma-carboxylation and 
thus activation of vitamin K-dependent clotting proteins.  
However, since the functionalisation of both factor Xa and thrombin is inextricably 
linked to vitamin K, there is the possibility that the pharmacological activity of agents that inhibit 
these proteins could be influenced by alterations in vitamin K availability. Indeed in an earlier 
study in rats we demonstrated that vitamin K deficiency significantly enhanced the 
anticoagulation activity of the direct thrombin inhibitor, ximelagatran. Briefly, the anticoagulant 
activity of ximelagatran (20 mmol/kg, twice daily for 8 days) was significantly greater in rats on 
vitamin K deficient diet (12.3-fold for prothrombin time, 5.1-fold for activated partial 
thromboplastin time, and 1.6-fold for ecarin clotting time) compared to those on normal diet. 
Factor II activity was reduced to 58% by ximelagatran in rats on normal diet. However, factor 
II activity was virtually abolished (<1%) by the drug in rats on vitamin K deficient diet.(91) 
Whether dietary vitamin K influences anticoagulation response to DOACs in man remains to 
be investigated.  
 
Conclusions 
Long-term oral anticoagulation with warfarin and other vitamin K antagonists places 
major limitations on patients in terms of what they can eat and drink. In particular, patients 
need to maintain a consistent dietary intake of vitamin K, as sudden or marked changes in the 
intake of this vitamin (which can often be unintentional, e.g. initiation or withdrawal of dietary 
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supplementation) can have a dramatic effect on anticoagulation control that can increase the 
risk of either thromboembolism due to under-coagulation or bleeding due to over-
anticoagulation. To minimise such risks to the patient it is therefore necessary to carry out 
additional INR monitoring and dose adjustment with the associated increase in the cost of 
anticoagulation therapy and the reduction in patient quality of life. Appropriate education of 
patients regarding the effects of diet and dietary supplementation on anticoagulation, 
emphasising the potential dangers of any sudden or marked changes in these factors, is 
therefore an important aspect of anticoagulation care. However, while improved patient 
education may help to reduce the risk of suboptimal anticoagulation control related to dietary 
changes in patients receiving long-term thromboprophylaxis with warfarin, clearly this will 
remain a difficult problem for many patients and their healthcare providers. Daily 
supplementation with oral vitamin K would be a good option in the attempt to improve 
anticoagulation control in patients with unstable anticoagulation suspected of having poor 
diets. 
 
Expert commentary 
There is a clear absence of consistency in the dietary intake among patients that 
receive warfarin or other vitamin K antagonists. Changing the dietary preferences or adding 
certain sources in patients’ diet is not an effective and practical way of maintaining a stable 
anticoagulation control. Nevertheless, numerous studies including one from our group have 
shown that daily low dose oral vitamin K supplementation (100 to 200 mg) can improve 
anticoagulation outcomes and is simple to implement, because it does not interfere with 
individual dietary preference. 
As part of the clinical management of patients on warfarin therapy, there should be a 
greater awareness among healthcare providers of the impact of malnutrition (in terms of dietary 
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vitamin K intake), and the various foods and beverages that contain varying amounts of vitamin 
K on anticoagulation control.  
There is experimental evidence in animals to suggest that ximelagatran interacts with 
dietary vitamin K. Further studies are needed to ascertain the presence of a 
pharmacodynamics interaction between dietary vitamin K and DOACs in man.   
 
Five-year view 
There is a compelling body of evidence on the impact of variable and poor dietary 
vitamin K on anticoagulation stability and the risk of bleeding in patients on warfarin therapy. 
Daily supplementation with low doses of oral vitamin K which leads to stabilisation of vitamin 
K stores in the liver have been shown to improve anticoagulation control in previously unstable 
patients. We along with a number of other anticoagulation services have adopted this 
approach. However, it is important that the benefits of vitamin K supplementation in patients 
on long-term therapy in the attempt to improving the safety of warfarin therapy are recognised 
on a wider scale. We are currently investigating the potential impact of dietary vitamin K on 
anticoagulation response to DOACs in man. The results of these studies are expected to 
become available soon. Should the results of these studies demonstrate the existence of an 
interaction between DOACs and dietary vitamin K then for patient safety reasons the 
introduction of some form of monitoring may become necessary.  
 
Key issues 
 Variable dietary vitamin K intake affects anticoagulation response to warfarin. 
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 Warfarin interacts with a variety of foods, herbs and dietary supplements, which 
necessitates the need for better patient education about the effect of diet on 
anticoagulation control.  
 Daily supplementation with low oral dose vitamin K increases stability of 
anticoagulation. Vitamin K supplementation has been embedded into guidelines for 
the management of anticoagulation with vitamin K antagonists.  
 
Financial and competing interests disclosure: The authors report no conflicts of interest. 
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Table 1. Phylloquinone (vitamin K1) content of foods (92) 
Food item Phylloquinone 
content (µg/100g) 
Food item Phylloquinone 
content (µg/100g) 
Vegetables  Protein sources  
Collard greens 440 Dry soybeans 47 
Spinach 380 Dry lentils 22 
Salad greens 315 Liver 5 
Broccoli 180 Eggs 2 
Brussels sprouts 177 Fresh meats <1 
Cabbage 145 Fresh fish <1 
Bibb lettuce 122 Whole milk <1 
Asparagus 60 Tuna in oil 24 
Okra 40   
Iceberg lettuce 35 Prepared foodsa  
Green beans 33 Salad dressings 100 
Green peas 24 Coleslaw 80 
Cucumber 20 Mayonnaise 41 
Cauliflower 20 Beef chow mein 31 
Carrots 10 Muffins 25 
Tomatoes 6 Doughnuts 10 
Potatoes 1 Apple pie 11 
  Potato chips 15 
Fats and oils  French fries 5 
Soybean oil 193 Macaroni cheese 5 
Canola oil 127 Lasagne 5 
Cottonseed oil 60 Pizza 4 
Olive oil 55 Hamburger/bun 4 
Corn oil 3 Hot dog/bun 3 
Margarinea 42 Baked beans 3 
Butter 7 Bread 3 
a Phylloquinone content may vary widely according to the source of oil used. 
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Table 2. Adequate Intake (AI) of vitamin K (15) 
Life Stage Age Vitamin K (μg/day) 
Infants 
0-6 months 2.0 
7-12 
months 
2.5 
Children 
1-3 years 30 
4-8 years 55 
9-13 years 60 
Adolescent
s 
14-18 years 75 
Adults > 19 years 
120 (males) 
90 (females) 
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Table 3. The K-Card (vitamin K intake assessment card) (from Couris et al. 2000) 
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Table 4. Vitamin K content of various enteral feeds ready-to-drink according to the British 
National Formulary, 2017^ 
Product Kcal Vitamin K content (μg) 
 Per 100mL serving  
Fresubin® original a 100 6.7 
Fresubin® original fibre a 100 6.7 
Fresubin® 1000 complete a 418 10 
Fresubin® 1200 complete a 500 10 
Fresubin® 1500 complete a 420 6.7 
Fresubin® 1800 complete a 500 10 
Fresubin® 2250 complete a 
Fresubin® energy a 
Fresubin® energy fibre a 
Fresubin® HP energy a 
630 6.67 
Ensure TwoCal b 200 8.5 
Nutrison® c 
Nutrison® MCT c 
100 5.3 
Nutrison® Multi Fibre c 103 5.3 
Nutrison® Energy c 150 8 
Nutrison® Energy Multi Fibre c 153 8 
Nutrison® Protein Plus c 125 6.6 
Nutrison® Protein Plus Multi Fibre c 128 6.6 
Nutrison® 800 Complete Multi Fibre c 83 8 
Nutrison® 1000 Complete Multi Fibre c 104 8 
Resource Energy d 151 14 
Peptamen® HN d 133 9 
Vital 1.5kcal b 150 7 
Novasource® GI Control d 106 6 
Novasource® GI Control d 155 11 
   
 Per 8 fl oz serving *  
Jevity® 1 Cal b 250 15 
Jevity 1.2 Cal (formerly Jevity Plus) b 285 20 
Jevity® 1.5 Cal b 355 19 
Osmolite® 1 Cal b 250 15 
Osmolite® 1.2 Cal b 285 20 
Osmolite® 1.5 Cal b 355 19 
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Ensure® b 220 20 
Ensure® High Protein b 160 20 
Ensure® Plus b 350 20 
Ensure® Plus HN b 250 20 
Ensure® Enlive® Advanced Nutrition 
Shake b 
350 20 
Two cal® b 475 20 
Perative® b 308 17 
 
^ Information retrieved from https://www.evidence.nhs.uk/formulary/bnf/current/; accessed 14 
February, 2017) 
 
a Information retrieved from Fresenius Kabi (http://www.fresenius-kabi.co.uk/4727.htm; 
accessed 14 February, 2017) 
 
b Information retrieved from Abbott (https://abbottnutrition.com/; accessed 14 February, 2017) 
c Information retrieved from Nutricia Clinical (http://www.nutricia.co.uk/; accessed 15 
February, 2017) 
 
d Information retrieved from Nestlé HealthCare Nutrition 
(https://www.nestlehealthscience.co.uk;accessed 15 February, 2017) 
* 8 fl oz (US) = 237 ml 
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